Johnson & Johnson's Rybrevant Gets FDA Approval For Lung Cancer Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 01 2024
0mins
Source: Business Insider
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 234.340
Low
190.00
Averages
218.50
High
240.00
Current: 234.340
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of Trump's Drug Pricing Policy Impact
- Drug Pricing Policy: Trump's Most-Favored-Nation policy aims to cap U.S. drug prices to match those of other developed nations, potentially impacting government programs like Medicare and leading to decreased sales and profits for drugmakers.
- Strong Revenue Outlook: Despite challenges from drug price negotiations, Johnson & Johnson expects to achieve $100.8 billion in revenue for 2023, reflecting a 7% year-over-year increase and demonstrating resilience in its diversified healthcare portfolio.
- New Product Development: Johnson & Johnson is seeking U.S. approval for its robotic-assisted surgery device, the Ottava system, which, despite competition, could benefit from the growing demand for minimally invasive procedures due to an aging population.
- Acquisition and Growth: Roche's acquisition of SAGA Diagnostics for up to $595 million aims to strengthen its position in the molecular residual disease testing market, which is one of the fastest-growing areas in diagnostics, potentially offsetting pressures from drug pricing policies.
See More
Trump's Drug Price Policy Could Impact Pharma Profits
- Drug Pricing Policy: Trump's Most-Favored-Nation policy aims to limit the prices the U.S. government pays for certain drugs, potentially triggering a domino effect on pharmaceutical companies' sales and profits in the world's largest pharmaceutical market.
- Strong Revenue Outlook: Despite challenges from drug price negotiations, Johnson & Johnson expects to achieve $100.8 billion in revenue this year, reflecting a 7% year-over-year increase and showcasing its resilience and adaptability in the diversified healthcare sector.
- Acquisition and Innovation: Roche's acquisition of SAGA Diagnostics, costing up to $595 million, aims to strengthen its position in the rapidly growing molecular residual disease testing market for cancer, which is expected to drive growth in its diagnostics business.
- Diversification Advantage: The diversified portfolios of Johnson & Johnson and Roche enable them to maintain competitiveness under Trump's drug pricing policies, particularly through ongoing innovation and investment in medical devices and diagnostics.
See More
Johnson & Johnson Acquires Gemtrack Technology Rights
- Technology Acquisition: Johnson & Johnson's DePuy Synthes has acquired rights to develop, manufacture, and commercialize Gemtrack technology from MinMax Medical, aiming to advance radiofrequency tracking in joint reconstruction surgeries and potentially set a new industry standard.
- Market Potential: The Gemtrack RF tracking technology is expected to eliminate the need for infrared cameras, reduce reliance on invasive anchors, and enable continuous, highly accurate real-time tracking, thereby enhancing surgical safety and efficiency.
- Application Scope: This technology can be applied to shoulder, hip, and knee procedures for navigation and robotic assistance, strengthening DePuy Synthes's competitive position in orthopedic surgery and addressing market demands for high-precision operations.
- Strategic Implications: By integrating Gemtrack technology, DePuy Synthes not only enhances the technological sophistication of its product line but also positions itself to lead in the future medical device market, driving long-term growth for the company.
See More
Declining Appeal of U.S. Treasuries Amid Rising Corporate Debt Interest
- Rising Treasury Yields: The yield on the two-year Treasury note has increased by 60 basis points this year, surpassing 4.00%, primarily due to the energy price surge from the Iran war, which is expected to compel the Federal Reserve to raise interest rates, thereby heightening investor concerns about Treasuries.
- Strong Corporate Debt Performance: Many blue-chip companies have outperformed Treasuries, with Apple's two-year bond yield narrowing to just 3 basis points above the Treasury yield, marking a record low spread and indicating a growing appeal of corporate debt over government bonds.
- Credit Rating Discrepancies: Microsoft and Johnson & Johnson are the only U.S. companies to hold AAA ratings from the three major agencies, while the U.S. government no longer has a AAA rating, reflecting that the risk of lending to corporations is now comparable to that of Treasuries, prompting investors to reassess risk-reward dynamics.
- Long-Term Investment Concerns: While corporate debt is viewed as lower risk, investors must consider long-term repayment capabilities, especially amid escalating global AI competition, which introduces uncertainties about companies' futures and their ability to meet debt obligations.
See More
Comparing Dividend Kings: Procter & Gamble vs. Johnson & Johnson
- Dividend King Criteria: To be classified as a Dividend King, a company must increase its dividend for at least 50 consecutive years, a standard that highlights the ability of firms like Procter & Gamble and Johnson & Johnson to maintain stability through economic fluctuations, showcasing their robust business models and brand loyalty.
- Procter & Gamble's Market Position: With a market cap of $336 billion and a dividend yield of 2.95%, Procter & Gamble is considered a solid investment choice despite its valuation metrics being below five-year averages, particularly as consumer demand for essentials remains consistent amid economic uncertainty.
- Johnson & Johnson's Competitive Edge: Johnson & Johnson boasts a market cap of $564 billion and a 5.7% annual dividend growth rate, benefiting from patent protections in its pharmaceutical and medical device sectors, which ensures stable revenue streams even during economic downturns, reinforcing its leadership in the healthcare industry.
- Legal Risks and Market Opportunities: While Johnson & Johnson faces legal challenges related to talcum powder, its diversified business model and ongoing investment in research and development position it well to navigate market uncertainties, further solidifying its status as a Dividend King.
See More
Johnson & Johnson: A Strong Dividend King Investment
- Stable Dividend Growth: Johnson & Johnson has increased its dividend annually for 50 consecutive years, with an average growth rate of 5.7%, demonstrating a robust business model and adaptability in the face of economic uncertainty, which attracts long-term investor interest.
- Strong Demand for Medical Products: J&J's medical and pharmaceutical products benefit from patent protections, ensuring its market position in healthcare, as consumers have little choice when it comes to necessary medical services, thereby enhancing revenue stability and risk resilience.
- Relative Valuation Analysis: Although J&J's valuation metrics are above its five-year averages, its dividend yield exceeds 2.2%, double that of the broader market, indicating that investors are willing to pay a premium for its diversified and resilient business in the current market environment.
- Legal Risk Consideration: J&J faces legal challenges related to talcum powder, which may concern some investors; however, the management's ability to address these issues could further validate the company's fundamental strength and capacity to navigate adversity.
See More
Analysis of Trump's Drug Pricing Policy Impact
- Drug Pricing Policy: Trump's Most-Favored-Nation policy aims to cap U.S. drug prices to match those of other developed nations, potentially impacting government programs like Medicare and leading to decreased sales and profits for drugmakers.
- Strong Revenue Outlook: Despite challenges from drug price negotiations, Johnson & Johnson expects to achieve $100.8 billion in revenue for 2023, reflecting a 7% year-over-year increase and demonstrating resilience in its diversified healthcare portfolio.
- New Product Development: Johnson & Johnson is seeking U.S. approval for its robotic-assisted surgery device, the Ottava system, which, despite competition, could benefit from the growing demand for minimally invasive procedures due to an aging population.
- Acquisition and Growth: Roche's acquisition of SAGA Diagnostics for up to $595 million aims to strengthen its position in the molecular residual disease testing market, which is one of the fastest-growing areas in diagnostics, potentially offsetting pressures from drug pricing policies.
See More
Trump's Drug Price Policy Could Impact Pharma Profits
- Drug Pricing Policy: Trump's Most-Favored-Nation policy aims to limit the prices the U.S. government pays for certain drugs, potentially triggering a domino effect on pharmaceutical companies' sales and profits in the world's largest pharmaceutical market.
- Strong Revenue Outlook: Despite challenges from drug price negotiations, Johnson & Johnson expects to achieve $100.8 billion in revenue this year, reflecting a 7% year-over-year increase and showcasing its resilience and adaptability in the diversified healthcare sector.
- Acquisition and Innovation: Roche's acquisition of SAGA Diagnostics, costing up to $595 million, aims to strengthen its position in the rapidly growing molecular residual disease testing market for cancer, which is expected to drive growth in its diagnostics business.
- Diversification Advantage: The diversified portfolios of Johnson & Johnson and Roche enable them to maintain competitiveness under Trump's drug pricing policies, particularly through ongoing innovation and investment in medical devices and diagnostics.
See More
Johnson & Johnson Acquires Gemtrack Technology Rights
- Technology Acquisition: Johnson & Johnson's DePuy Synthes has acquired rights to develop, manufacture, and commercialize Gemtrack technology from MinMax Medical, aiming to advance radiofrequency tracking in joint reconstruction surgeries and potentially set a new industry standard.
- Market Potential: The Gemtrack RF tracking technology is expected to eliminate the need for infrared cameras, reduce reliance on invasive anchors, and enable continuous, highly accurate real-time tracking, thereby enhancing surgical safety and efficiency.
- Application Scope: This technology can be applied to shoulder, hip, and knee procedures for navigation and robotic assistance, strengthening DePuy Synthes's competitive position in orthopedic surgery and addressing market demands for high-precision operations.
- Strategic Implications: By integrating Gemtrack technology, DePuy Synthes not only enhances the technological sophistication of its product line but also positions itself to lead in the future medical device market, driving long-term growth for the company.
See More
Declining Appeal of U.S. Treasuries Amid Rising Corporate Debt Interest
- Rising Treasury Yields: The yield on the two-year Treasury note has increased by 60 basis points this year, surpassing 4.00%, primarily due to the energy price surge from the Iran war, which is expected to compel the Federal Reserve to raise interest rates, thereby heightening investor concerns about Treasuries.
- Strong Corporate Debt Performance: Many blue-chip companies have outperformed Treasuries, with Apple's two-year bond yield narrowing to just 3 basis points above the Treasury yield, marking a record low spread and indicating a growing appeal of corporate debt over government bonds.
- Credit Rating Discrepancies: Microsoft and Johnson & Johnson are the only U.S. companies to hold AAA ratings from the three major agencies, while the U.S. government no longer has a AAA rating, reflecting that the risk of lending to corporations is now comparable to that of Treasuries, prompting investors to reassess risk-reward dynamics.
- Long-Term Investment Concerns: While corporate debt is viewed as lower risk, investors must consider long-term repayment capabilities, especially amid escalating global AI competition, which introduces uncertainties about companies' futures and their ability to meet debt obligations.
See More
Comparing Dividend Kings: Procter & Gamble vs. Johnson & Johnson
- Dividend King Criteria: To be classified as a Dividend King, a company must increase its dividend for at least 50 consecutive years, a standard that highlights the ability of firms like Procter & Gamble and Johnson & Johnson to maintain stability through economic fluctuations, showcasing their robust business models and brand loyalty.
- Procter & Gamble's Market Position: With a market cap of $336 billion and a dividend yield of 2.95%, Procter & Gamble is considered a solid investment choice despite its valuation metrics being below five-year averages, particularly as consumer demand for essentials remains consistent amid economic uncertainty.
- Johnson & Johnson's Competitive Edge: Johnson & Johnson boasts a market cap of $564 billion and a 5.7% annual dividend growth rate, benefiting from patent protections in its pharmaceutical and medical device sectors, which ensures stable revenue streams even during economic downturns, reinforcing its leadership in the healthcare industry.
- Legal Risks and Market Opportunities: While Johnson & Johnson faces legal challenges related to talcum powder, its diversified business model and ongoing investment in research and development position it well to navigate market uncertainties, further solidifying its status as a Dividend King.
See More
Johnson & Johnson: A Strong Dividend King Investment
- Stable Dividend Growth: Johnson & Johnson has increased its dividend annually for 50 consecutive years, with an average growth rate of 5.7%, demonstrating a robust business model and adaptability in the face of economic uncertainty, which attracts long-term investor interest.
- Strong Demand for Medical Products: J&J's medical and pharmaceutical products benefit from patent protections, ensuring its market position in healthcare, as consumers have little choice when it comes to necessary medical services, thereby enhancing revenue stability and risk resilience.
- Relative Valuation Analysis: Although J&J's valuation metrics are above its five-year averages, its dividend yield exceeds 2.2%, double that of the broader market, indicating that investors are willing to pay a premium for its diversified and resilient business in the current market environment.
- Legal Risk Consideration: J&J faces legal challenges related to talcum powder, which may concern some investors; however, the management's ability to address these issues could further validate the company's fundamental strength and capacity to navigate adversity.
See More
